Recent Updates on the Role of Nanoparticles in the Treatment of Viral Diseases.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2021-01-01 DOI:10.1615/CritRevTherDrugCarrierSyst.2020034715

Anam Javaid, Duaa Zahra, Ayesha Asim, Nehdia Javaid, Usman Ali Ashfaq

{"title":"Recent Updates on the Role of Nanoparticles in the Treatment of Viral Diseases.","authors":"Anam Javaid, Duaa Zahra, Ayesha Asim, Nehdia Javaid, Usman Ali Ashfaq","doi":"10.1615/CritRevTherDrugCarrierSyst.2020034715","DOIUrl":null,"url":null,"abstract":"<p><p>Viral infections such as AIDS, hepatitis, herpes keratitis, and herpes labialis became resistant to drugs and it is difficult to design vaccine. In current era drug-resistant viruses are now treated by nanoparticles (NPs) and this field is known as nanobiotechnology that relates nanoscience with the biological system. NPs due to their antiviral activity are used in the treatment of viral diseases. The advantages of using the NP is its specific target action and increase the efficiency of treatment with minimum side effects. Liposomes, quantum dots, polymeric NPs, solid lipid NPs, silver NPs, gold NPs, and magnetic NPs are used to treat viral infections. NP-based therapeutics have completely replaced the usage of drugs and vaccines for viral diseases treatment. Nano vaccines have been investigated for the delivery of drugs; biomaterials-based NPs are in development to be formulated into nano vaccines. But there are limitations in the manufacturing and stabilization of NPs in the body. This review focuses on the antiviral activity of several NPs, its uptake by different viruses for viral disease treatment, nano vaccines, and the limitation of the NPs as nanotherapeutics.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 2","pages":"75-102"},"PeriodicalIF":3.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2020034715","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

Viral infections such as AIDS, hepatitis, herpes keratitis, and herpes labialis became resistant to drugs and it is difficult to design vaccine. In current era drug-resistant viruses are now treated by nanoparticles (NPs) and this field is known as nanobiotechnology that relates nanoscience with the biological system. NPs due to their antiviral activity are used in the treatment of viral diseases. The advantages of using the NP is its specific target action and increase the efficiency of treatment with minimum side effects. Liposomes, quantum dots, polymeric NPs, solid lipid NPs, silver NPs, gold NPs, and magnetic NPs are used to treat viral infections. NP-based therapeutics have completely replaced the usage of drugs and vaccines for viral diseases treatment. Nano vaccines have been investigated for the delivery of drugs; biomaterials-based NPs are in development to be formulated into nano vaccines. But there are limitations in the manufacturing and stabilization of NPs in the body. This review focuses on the antiviral activity of several NPs, its uptake by different viruses for viral disease treatment, nano vaccines, and the limitation of the NPs as nanotherapeutics.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纳米颗粒在病毒性疾病治疗中的作用研究进展。

艾滋病、肝炎、疱疹性角膜炎和唇疱疹等病毒感染对药物产生了耐药性，很难设计疫苗。在当今时代，耐药病毒现在用纳米粒子(NPs)治疗，这一领域被称为纳米生物技术，它将纳米科学与生物系统联系起来。NPs由于其抗病毒活性而被用于病毒性疾病的治疗。使用NP的优点是其靶向性强，副作用小，提高治疗效率。脂质体、量子点、聚合NPs、固体脂质NPs、银NPs、金NPs和磁性NPs被用于治疗病毒感染。基于np的疗法已经完全取代了治疗病毒性疾病的药物和疫苗。已经研究了纳米疫苗用于药物输送;基于生物材料的纳米颗粒正在开发中，将被配制成纳米疫苗。但NPs在体内的制造和稳定存在局限性。本文综述了几种NPs的抗病毒活性、不同病毒对其治疗病毒性疾病的吸收、纳米疫苗以及NPs作为纳米疗法的局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical Reviews in Therapeutic Drug Carrier Systems 医学-药学

CiteScore

5.50

自引率

18.50%

发文量

审稿时长

>12 weeks

期刊介绍： Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.